Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table 20–3 Health Care Costs Associated with RSV Infections

 

% with Care

Cost per Unit

Units per Case

Form of Treatment

AGE<5

 

Upper Respiratory

 

pharyngitis, otitis media

100%

$50

1.0

physician a

 

100%

$50

1.0

diagnostic a

100%

$50

1.0

medication b

Bronchiolitis/pneumonia

 

outpatient only

100%

$50

1.0

physician a

 

100%

$50

1.0

diagnostic a

100%

$50

1.0

medication b

Bronchiolitis/pneumonia

 

inpatient

100%

$4,000

1.0

hospitalization

 

100%

$50

2.0

physician a

100%

$50

1.0

diagnostic a

100%

$50

1.0

medication b

AGE 5+

 

Upper Respiratory

 

pharyngitis, otitis media

100%

$50

1.0

physician a

 

100%

$50

1.0

diagnostic a

100%

$50

1.0

medication b

Bronchiolitis/pneumonia

 

outpatient only

100%

$50

1.0

physician a

 

100%

$50

1.0

diagnostic a

100%

$50

1.0

medication b

Bronchiolitis/pneumonia

 

inpatient

100%

$4,000

1.0

hospitalization

 

100%

$50

2.0

physician a

100%

$50

1.0

diagnostic a

100%

$50

1.0

medication b

Vaccine Schedule, Efficacy, and Costs

For the purposes of the calculations in this report, it was estimated that this vaccine would cost $50 per dose and that administration costs would be $10 per dose. Default assumptions of a 3-dose series and 75% effectiveness were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for RSV were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 33,000. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement